Pazopanib Associated With Slightly Longer Time Without Toxicity in RCC

Share this content:
Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazopanib had a moderately longer time without symptoms.
Patients with locally advanced or metastatic renal cell carcinoma randomly assigned to receive pazopanib had a moderately longer time without symptoms.

Patients with locally advanced or metastatic renal cell carcinoma (RCC) randomly assigned to receive pazopanib had a moderately longer time without symptoms or toxicity compared with sunitinib, a study published in the journal Cancer has shown.1

Findings from the open-label, phase 3 COMPARZ trial demonstrated that pazopanib was noninferior to sunitinib with respect to progression-free survival in treatment-naïve patients with metastatic RCC. Researchers reported results from a post-hoc analysis that evaluated overall treatment differences using quality-adjusted time without symptoms or toxicity (Q-TWiST) methodology.

For the study, participants were categorized into 1 of 3 health states: time with grade 3 or 4 toxicity, time without symptoms of disease or grade 3/4 toxicity of treatment, and time after disease progression or relapse. Researchers then calculated the Q-TWiST after weighting the time spent in each state by a health-state utility associated with that state.

Results showed that the average time with grade 3 or 4 toxicity was 31 days (95% CI, 13 - 48) longer for sunitinib compared with pazopanib. In a threshold utility analysis, researchers found that the Q-TWiST ranged from -11 days to 43 days in favor of pazopanib for most utility combinations, but significant differences typically occurred when the utility for time with grade 3 or 4 toxicity was lower than that for time after tumor progression or relapse.

RELATED: Study Evaluates Cediranib Plus Saracatinib in Relapsed mRCC

“Patients randomized to pazopanib had a slightly longer Q-TWiST in comparison with sunitinib patients, and this was primarily due to the reduced length of [time with grade 3 or 4 toxicity],” the authors concluded.

Reference

  1. Beaumont JL, Salsman JM, Diaz J, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma [published online ahead of print January 27, 2016]. Cancer. doi: 10.1002/cncr.29888.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs